Loss of Response to Anti-Tumor Necrosis Factor Alpha Therapy in Patients With Inflammatory Bowel Disease: A Real-World Comparison of Combination Therapy Versus Monotherapy.

JGH Open · 2026 · PMC13097357 · PMID 42022942

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

This benefit was most evident in patients receiving IFX, whereas reduction in sLOR with ADA did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.